Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

On February 9, Eli Lilly agreed to buy Orna Therapeutics

Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Orna Therapeutics, a Massachusetts-based biotech firm specializing in circular RNA

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top